Black Rock Inc. Theseus Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$2.12 - $4.18 $179,678 - $354,271	84,754 Added 6.32%	1,425,234 $5.77 Million
Q3 2023 Nov 13, 2023	BUY	$2.66 - $10.04 $17,587 - $66,384	6,612 Added 0.5%	1,340,480 $3.61 Million
Q2 2023 Aug 11, 2023	BUY	$7.28 - $11.82 $3.28 Million - $5.32 Million	450,406 Added 50.98%	1,333,868 $12.4 Million
Q1 2023 May 12, 2023	BUY	$5.21 - $14.05 $95,890 - $258,590	18,405 Added 2.13%	883,462 $7.85 Million
Q4 2022 Feb 13, 2023	BUY	$4.69 - $8.36 $419,600 - $747,944	89,467 Added 11.54%	865,057 $4.31 Million

Q3 2022 Nov 14, 2022	BUY	$5.7 - $8.68 $502,916 - $765,845	88,231 Added 12.84%	775,590 $4.5 Million
Q2 2022 Aug 12, 2022	BUY	$5.04 - $14.05 $718,220 - $2 Million	142,504 Added 26.15%	687,359 $3.8 Million
Q1 2022 May 12, 2022	BUY	$8.75 - $14.51 $101,430 - $168,199	11,592 Added 2.17%	544,855 $6.28 Million
Q4 2021 Feb 10, 2022	BUY	$8.98 - $20.09 $4.79 Million - $10.7 Million	533,263 New	533,263 $6.76 Million

1.06M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.